FDA Lifts Clozapine Registry, but Prescriber Fear Persists — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- FDA retired on Feb. 24, 2025 the 30-year-old clozapine monitoring registry (REMS), ending mandatory blood-draw logging that had to clear a national database before pharmacies could dispense the drug.
- Clozapine is the only FDA-approved drug for treatment-resistant schizophrenia and the only antipsychotic shown to reduce suicide, yet only about 4% of US schizophrenia patients receive it, though roughly a third could benefit.
- Dr. Nitin Gogtay spent nearly two decades running blinded clozapine trials in children with childhood-onset schizophrenia at the National Institute of Mental Health, and recently could not find a single child psychiatrist across four academic centers willing to start clozapine in a child patient.
- Neutropenia risk from clozapine concentrates in the first months of treatment; Gogtay's NIMH group showed adding lithium can lift neutrophil counts enough to keep children safely on the drug, and published the finding.
- The FDA still recommends blood monitoring but no longer forces it, shifting the responsibility for risk management from a federal registry to clinician judgment and informed patient choice.
- Gogtay argues clinicians have historically cycled through four or five less-effective medications before reaching clozapine, and that parents — often desperate after exhausting options — were rarely the obstacle; clinicians' fear was.
Why it matters: For the roughly one-third of schizophrenia patients whose illness does not respond to other antipsychotics, the practical bottleneck was never just the paperwork but clinician aversion to a drug with a feared safety profile. With the REMS gone, the ~96% of US patients who could benefit from clozapine but don't get it now depend on whether prescribers — especially the few who treat children with childhood-onset schizophrenia — can overcome that fear.
Ask SkimNews
